<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04029805</url>
  </required_header>
  <id_info>
    <org_study_id>P044</org_study_id>
    <nct_id>NCT04029805</nct_id>
  </id_info>
  <brief_title>Evaluation of a Combination of a Plant Extract and a Probiotic on Glucidic Metabolism in Women With PCOS and High Insulin Levels</brief_title>
  <official_title>Evaluation of the Effect of a Combination of a Plant Extract (BSL_EP044) and Lactobacillus BSL_PS6 on Glucidic Metabolism in Women Suffering From Polycystic Ovary Syndrome and High Insulin Levels</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biosearch S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biosearch S.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the present study is to evaluate the effect of the combination of a plant extract
      (BSL_EP044) and Lactobacillus BSL_PS6 on parameters of the glucidic metabolism,
      anthropometric parameters, hormonal levels and the menstrual cycle in women with polycystic
      ovary syndrome and high insulin levels.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Polycystic ovary syndrome (PCOS) is the most prevalent endocrinopathy in women, affecting
      4-15% of those who are of childbearing age. It is a complex and heterogeneous disease in
      which the gynecological disorder coexist with metabolic problems such as insulin resistance.

      The beneficial effect of the extract plant BSL-EP044 on glycemic metabolism in women with
      PCOS is widely studied and demonstrated and Lactobacillus BSL_PS6 appears to exert a
      synergistic effect by supplementing the effect of BSL-EP044. The hypothesis of our study is
      that the addition of the probiotic strain Lactobacillus BSL_PS6 to extract plant BSL-EP044
      treatment may improve the beneficial effect of this one on insulin resistance and other
      metabolic alterations related to PCOS.

      The main objective of the present study is to evaluate the effect of the combination of a
      Plant Extract (BSL_EP044) and Lactobacillus BSL_PS6 on parameters related to glycemic
      metabolism in women with polycystic ovary syndrome and high insulin levels.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 29, 2019</start_date>
  <completion_date type="Anticipated">August 30, 2020</completion_date>
  <primary_completion_date type="Actual">May 30, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma insulin</measure>
    <time_frame>12 weeks</time_frame>
    <description>Levels of plasma insulin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma glucose</measure>
    <time_frame>12 weeks</time_frame>
    <description>Levels of plasma glucose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HOMA</measure>
    <time_frame>12 weeks</time_frame>
    <description>Insulin sensitivity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total testosterone</measure>
    <time_frame>12 weeks</time_frame>
    <description>Total testosterone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Free testosterone</measure>
    <time_frame>12 weeks</time_frame>
    <description>Free testosterone</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Weight</measure>
    <time_frame>12 weeks</time_frame>
    <description>Weight variation throughout the study</description>
  </other_outcome>
  <other_outcome>
    <measure>BMI</measure>
    <time_frame>12 weeks</time_frame>
    <description>Body mass index</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood pressure</measure>
    <time_frame>12 weeks</time_frame>
    <description>Systolic and diastolic pressure during the study</description>
  </other_outcome>
  <other_outcome>
    <measure>Ovarian cycle</measure>
    <time_frame>12 weeks</time_frame>
    <description>Duration of the ovarian cycle</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Polycystic Ovarian Syndrome</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Combination of a Plant Extract and a Probiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Volunteers will take twice at day for 12 weeks a capsule containing the combination of a plant extract (BSL_EP044) and Lactobacillus BSL_PS6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Volunteers will take twice at day for 12 weeks a capsule containing maltodextrin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Combination of a plant extract (BSL_EP044) and Lactobacillus BSL_PS6</intervention_name>
    <description>Each participant will consume 2 capsules daily, in the morning and at night without any restriction in the diet nor in their habits of life.</description>
    <arm_group_label>Combination of a Plant Extract and a Probiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Each participant will consume 2 capsules daily, in the morning and at night without any restriction in the diet nor in their habits of life.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Being diagnosed with polycystic ovarian syndrome according to the Rotterdam criteria.

          -  HOMA values between 2.5 and 3.

          -  Body mass index of less than 35 kg/m2.

          -  Accept freely to participate in the study and sign the informed consent document.

        Exclusion Criteria:

          -  Women in treatment with oral antidiabetics.

          -  Being pregnant or intending to get pregnant.

          -  Be in fertility treatment.

          -  To suffer from other diseases that affect the hormonal response or that could
             interfere with the glucidic metabolism.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolás Mendoza, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor of Gynecology at the Faculty of Medicine of the University of Granada</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Juristo Fonollá, PhD</last_name>
    <phone>+34958240288</phone>
    <email>Juristo.FonollaJoya@biosearchlife.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinica Margen</name>
      <address>
        <city>Granada</city>
        <state>Andalucia</state>
        <zip>18006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 22, 2019</study_first_submitted>
  <study_first_submitted_qc>July 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2019</study_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Polycystic ovarian syndrome</keyword>
  <keyword>Extract plant</keyword>
  <keyword>Probiotics</keyword>
  <keyword>Insulin resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

